---
audienceLevel: patient
cancerTypes:
- lung
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Osimertinib Mesylate - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/osimertinib
version: v1
---

# Osimertinib Mesylate - NCI

# Osimertinib Mesylate

Placeholder slot

(OH-sih-MER-tih-nib MEH-zih-layt)

This page contains brief information about osimertinib mesylate
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Tagrisso

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7&audience=consumer)

## Use in Cancer

Osimertinib mesylate
is approved to treat:

- **[Non-small cell lung cancer](/Common/PopUps/popDefinition.aspx?id=45323&version=Patient&language=English)** that has an abnormal *[EGFR](/Common/PopUps/popDefinition.aspx?id=796876&version=Patient&language=English)* gene. It is used in adults:
- who have had surgery to remove the cancer, to help keep the cancer from coming back after surgery
- with [stage IIIA](/Common/PopUps/popDefinition.aspx?id=45367&version=Patient&language=English), [stage IIIB](/Common/PopUps/popDefinition.aspx?id=682421&version=Patient&language=English), or [stage IIIC](/Common/PopUps/popDefinition.aspx?id=793422&version=Patient&language=English) cancer that cannot be removed by surgery and did not get worse during or after
[platinum](/Common/PopUps/popDefinition.aspx?id=45841&version=Patient&language=English)-based [chemoradiation therapy](/Common/PopUps/popDefinition.aspx?id=306495&version=Patient&language=English)
- as the first treatment for cancer that has spread to other parts of the body
- with [pemetrexed disodium](/Common/PopUps/popDefinition.aspx?id=45456&version=Patient&language=English) and platinum-based chemotherapy as the first treatment for cancer that has spread to other parts of the body
- with cancer that has spread to other parts of the body and got worse during or after treatment with another [EGFR tyrosine kinase inhibitor](/Common/PopUps/popDefinition.aspx?id=491502&version=Patient&language=English)

Osimertinib mesylate
is also being studied in the treatment of other types of
cancer.

## More About Osimertinib Mesylate

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/747632) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Osimertinib Mesylate](https://medlineplus.gov/druginfo/meds/a616005.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Lung Cancer Trial of Osimertinib Draws Praiseâ€”and Some Criticism](https://www.cancer.gov/news-events/cancer-currents-blog/2023/osimertinib-lung-cancer-adaura)

[Can Targeted Therapy for KRAS Mutations Double as Part of Immunotherapy?](https://www.cancer.gov/news-events/cancer-currents-blog/2022/kras-targeted-drugs-as-immunotherapy)

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Osimertinib](https://www.cancer.gov/research/participate/clinical-trials/intervention/C116377) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
